about
Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug ResponseEpigenetic Control of Haematopoietic Stem Cell Aging and Its Clinical ImplicationsEpigenetic regulation of hematopoietic stem cell agingPathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndromeEpigenetic Control of Stem Cell Potential during Homeostasis, Aging, and DiseaseHypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome PatientsDigging deep into "dirty" drugs - modulation of the methylation machinery.Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.How mRNA is misspliced in acute myelogenous leukemia (AML)?The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver.Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicineDiagnostics and Prognostication of Myelodysplastic Syndromes.Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
P2860
Q26772028-0E27B633-E12E-42AE-8EE3-BAB8946221FAQ26774949-1CCE6047-CDEA-434E-AA13-17267530D5A2Q27026054-39FF3977-E8FB-45FB-B542-9723EA9441EAQ34667249-A4EFE680-7911-4C51-9131-1239750D774EQ35227073-410EFD1A-4997-4B55-8005-821A38270A41Q35747943-EAA1D52E-40D5-42EF-980C-B8BB30347598Q36401117-E6619C7E-A5C3-4A30-A0DE-C4661E488211Q36523796-C8D07D60-62CF-4909-B586-63EF55BE344DQ36655704-BD9031B0-560F-48B4-862B-D0E0AFC47D2BQ36715982-8F0D2921-CC11-4A0A-A70F-6D4D86669A89Q37706037-FF0878C5-C977-4237-A4B4-BD4F6C8DEF43Q38226741-3DE4DD19-F7A4-4792-A9AC-36B87D7EB1C6Q38265600-52479FA6-E94F-4BE9-85B3-A04B9E44235BQ38570399-810FAE7D-63D1-47D1-8088-E25113C5FEE5Q38687894-D6B485E7-705B-40AD-98D3-AD1E46E6CE59Q38777440-BCC533CF-DAB2-447C-B6D1-872CFFCB913EQ40789369-9412795E-6D22-4169-8538-7EA759ABD244Q41331089-3B37AAD2-1EB0-4573-9E73-61BC726C2BAAQ41861253-A6407910-A671-4B59-889B-B915BE9E4D27Q42757406-CF01F97F-98CF-4A06-B57E-093F576F5D45Q49235235-983EA63A-58A7-4831-9CCE-5F31808F5577Q55080752-AD011DC9-4BD3-413C-AAC4-31A961C5C938Q55364989-BAB20172-38E3-49B3-9DA8-097DA5E3CC80
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Epigenetics of myelodysplastic syndromes.
@en
type
label
Epigenetics of myelodysplastic syndromes.
@en
prefLabel
Epigenetics of myelodysplastic syndromes.
@en
P2860
P356
P1433
P1476
Epigenetics of myelodysplastic syndromes.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2013.343
P577
2013-11-19T00:00:00Z
P5875
P6179
1004424609